What is Livzon Pharmaceutical Group Inc?
researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People's Republic of China and internationally.
LVZPF · Verdict
Solid reward · low risk
LVZPF scores well on cash flow and balance sheet with no major weaknesses flagged in the model.
Based on 88% data coverage
LVZPF · Verdict
20% free-cash-flow margin
Interest covered 32.7×
17% net margin · 16% ROE
Top decile vs peers
Above average
Model-based scoring. For information only — not financial advice.
researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People's Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, ilaprazole sodium for injection, and bismuth potassium citrate products for the gastrointestinal field; fluvoxamine maleate and perospirone hydrochloride tablets for the psychiatric and neurological field; and shenqi fuzheng injection and anti-viral granules for the traditional Chinese medicine field. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 4.63B, and a P/E ratio of 15.4x.
The scoring profile indicates moderate reward potential, with profitability and valuation as the leading contributors. Risk indicators are low, suggesting a relatively contained downside profile.
For informational purposes only. Not financial advice.